3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Unknown
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Carcinoma, Intraductal, Noninfiltrating
3
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HR Positive HER2 Negative Advanced Breast Cancer
1
HER2 Negative Breast Cancer
1
Fallopian Tube Neoplasms
1
Endometrial Stromal Tumors
1
ER+ Breast Cancer
1
Anatomic Stage III Breast Cancer AJCC v8
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
4
trastuzumab deruxtecan
2
elacestrant
2
Vinorelbine
2
AZD9833
2
toripalimab
1
talazoparib
1
ribociclib
1
pyrotinib
1
palbociclib
1
olaparib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
apatinib
1
abemaciclib
1
Selective Estrogen Receptor Modulators
1
Radiotherapy
1
RAD1901
1
Letrozole
1
Injections
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Capecitabine
1
Aromatase Inhibitors
1
Anastrozole
1
AZD5305
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Advanced Breast Cancer
×
Anastrozole
×
Clear all
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled